Archer Exploration & Adelaide University to develop carbon-based biosensor tech
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Archer Exploration Limited (ASX:AXE) has today announced that its existing collaboration agreement with The University of Adelaide, for the Australian Research Council Research Hub for Graphene Enabled Industry Transformation, has been redefined.
Under the new term, the collaboration will endeavour to develop and implement graphene and carbon-based materials for use in complex biosensing which can target applications in human health.
Research will explore graphene-based materials for complex biosensing to ideally generate patents with commercial applications — specifically towards the betterment of society — and will combine AXE’s graphite and graphene materials with the Research & Development capability of the university.
This agenda directly aligns with AXE’s vision of developing and integrating advanced materials, specifically in the focus area of human health for the betterment of society.
It’s worth noting that AXE is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.
The global biosensor market is forecast to grow from US$16 billion to US$27 billion from 2016 to 2022; it forms a niche segment of the US$328 billion global biotechnology market. Biosensors have a wide reach, with applications across a broad range of market segments such as medical testing, food toxicity, industrial processes, and environmental and agricultural testing.
The key focus for AXE’s collaboration with Adelaide University will be to develop generic biosensors that can address the largest of these market segments, medical testing; specifically, detection of cholesterol, blood glucose, blood gases, pregnancy, infectious diseases and drugs.
Commenting on the new agreement, AXE CEO Dr Mohammad Choucair said: “This is an exciting repositioning of our materials development focus with the University of Adelaide to target a high value, high growth market for innovative carbon-based technologies. This change is part of our strategy to capture niche segments of the carbon-based material’s market where we have potential competitive advantages as a vertically integrated participant.
“This is the first of our targeted efforts to capture and develop carbon-based solutions with Archer’s graphite and graphene materials through collaboration with The University of Adelaide, and one that offers significant upside potential for Archer.”
The company also stated in today’s announcement that the research activities were expected to result in “the development of all functional elements of a versatile in-vitro electrochemical carbon-based biosensor”. And, if successful, the materials “would be electronically, chemically and structurally tuneable with nanoscale-level optimisation tailored for electrochemical detection of complex biological molecule”.
Such a collaboration could provide AXE with new opportunities and markets to tap into, as it continues its ongoing development of its graphite resources.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.